Maze Therapeutics, Inc. (MAZE) FY2024 10-K Annual Report
Maze Therapeutics, Inc. (MAZE) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 31, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Maze Therapeutics, Inc. FY2024 10-K Analysis
Business Overview
- • Core business: Genetic medicine focused on novel drug discovery for complex diseases
- • No new products, services, or segments introduced or emphasized in FY 2025 filing
- • Continued emphasis on leadership with multiple new director appointments by March 31, 2025
- • Executive leadership consolidation: CEO Jason Coloma also acting as Principal Financial Officer
- • Filing lacks a formal business summary section, deviating from typical 10-K disclosures
Management Discussion & Analysis
- • Revenue $167.5M in 2024 vs $0 in 2023 from license agreements with Shionogi, Trace, Neurocrine
- • Net income $52.2M in 2024 vs net loss $100.4M in 2023; operating margin approx. 33.3% (income from operations $57.6M / revenue $167.5M) in 2024 vs negative in 2023
- • Best segment license revenue $167.5M in 2024 from Shionogi and others; worst segment research & development expenses $83.5M in 2024, up $9.6M YoY
- • Cash $196.8M end 2024; Series D preferred stock sale raised $70.8M; IPO proceeds net $127.8M in Feb 2025; no debt drawn from $50M credit facility
- • Management expects increasing R&D and G&A expenses; no commercial revenue forecasted; risk of financing shortfalls may delay operations or clinical programs
Risk Factors
- • No specific regulatory or legal risk disclosed in the section
- • No geopolitical or macroeconomic threat detailed in the section
- • Cybersecurity risk management led by Head of IT with 20+ years experience, ongoing monitoring and incident response program in place
- • No competitive or market disruption risk mentioned in the section
- • No financial or structural risk discussed in the section
Maze Therapeutics, Inc. FY2024 Key Financial MetricsXBRL
Revenue
$168M
Net Income
$52M
Operating Margin
34.4%
Net Margin
31.2%
ROE
-16.8%
Total Assets
$241M
EPS (Diluted)
$1.25
Operating Cash Flow
$76M
Source: XBRL data from Maze Therapeutics, Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Maze Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.